Polymix(500 IU+10000 IU)/gm

Polymix is a fixed-dose combination topical antibacterial used mainly for the prevention and treatment of minor superficial infections. Its use can be classified by strength of evidence as follows:

Established / approved uses

• Prevention of infection in minor cuts, scrapes, and minor thermal burns (first-aid use on intact or minimally broken skin).
• Treatment of minor superficial bacterial skin infections caused by susceptible organisms, primarily Staphylococcus aureus and Streptococcus pyogenes (bacitracin component) together with susceptible gram-negative organisms such as Pseudomonas aeruginosa and other Enterobacteriaceae (polymyxin B component).
• Ophthalmic ointment formulations of Polymix are indicated for superficial infections of the eye and its adnexa (e.g., blepharitis, blepharoconjunctivitis, and bacterial conjunctivitis) caused by susceptible organisms, when prescribed by a physician.

Adjunct / supportive use

• As an adjunct to routine minor wound care (cleaning and dressing) to reduce the risk of secondary bacterial infection; it does not replace proper wound cleansing.

Off-label / non-approved use

• Otic (ear) use is sometimes practiced off-label in some regions for minor external ear infections, but Polymix is not FDA-approved for this route and should only be used in the ear on specific medical advice.

Polymix is not adequate as sole therapy for deep, puncture, or seriously contaminated wounds, animal bites, or serious burns, which require medical evaluation.

Each formulation of Bacitracin Zinc + Polymyxin B Sulfate combines two antibacterial agents in a topical base:

• Bacitracin Zinc - commonly supplied as 400 to 500 units per gram in ointment formulations.
• Polymyxin B Sulfate - commonly supplied as 5,000 to 10,000 units per gram in ointment formulations.

Exact strengths vary by brand and dosage form (topical ointment, ophthalmic ointment, or powder); the topical base is typically white petrolatum, while ophthalmic preparations use an ophthalmic-grade ointment base free of irritants.

Polymix is a fixed-dose combination of two antibiotics belonging to different structural classes, formulated together to provide broad topical antibacterial coverage against both gram-positive and gram-negative organisms commonly implicated in minor skin and eye surface infections.

Bacitracin is a polypeptide antibiotic derived from Bacillus subtilis that is active mainly against gram-positive bacteria. Polymyxin B is a cationic cyclic polypeptide antibiotic derived from Bacillus polymyxa that is active mainly against gram-negative bacteria, including Pseudomonas aeruginosa. Because systemic absorption of both agents from intact skin is negligible, Polymix is formulated almost exclusively for topical (skin or ophthalmic) use rather than systemic administration.

Polymix belongs to the therapeutic class of topical antibacterial combinations (polypeptide antibiotics), used for skin and, in specific formulations, ophthalmic anti-infective purposes.

Bacitracin Zinc + Polymyxin B Sulfate combines two antibiotics with complementary and distinct mechanisms of action, giving it a broader antibacterial spectrum than either agent alone.

Bacitracin zinc

Bacitracin inhibits bacterial cell wall synthesis by binding to and blocking the dephosphorylation of the C55-isoprenyl pyrophosphate lipid carrier, a molecule required to transport peptidoglycan precursors across the bacterial cell membrane. This blocks synthesis of the cell wall, leading to bacterial cell lysis and death. It is primarily active against gram-positive organisms such as staphylococci and streptococci.

Polymyxin B sulfate

Polymyxin B acts as a cationic surfactant that binds to the lipopolysaccharide and phospholipid components of the outer cell membrane of gram-negative bacteria. This disrupts membrane integrity, increases permeability, and causes leakage of intracellular contents, resulting in bacterial cell death. It is active against gram-negative organisms, notably Pseudomonas aeruginosa, Escherichia coli, and other Enterobacteriaceae, but has minimal activity against most gram-positive organisms.

Together, the two components of Bacitracin Zinc + Polymyxin B Sulfate give combined activity against many of the bacteria responsible for minor skin and superficial eye infections. Systemic absorption through intact or minimally broken skin is negligible.

Polymix is for external (topical skin) or ophthalmic use only, depending on the formulation prescribed or purchased. It must never be swallowed, injected, or used systemically. Wash hands before and after application, avoid contact with the tube tip and the wound or eye surface, and follow the specific instructions for the formulation dispensed (skin ointment versus ophthalmic ointment).

Because Polymix is applied topically and systemic absorption through intact or minimally broken skin is negligible, clinically significant systemic drug interactions are uncommon. However, the following points are clinically relevant:

• Other nephrotoxic or ototoxic agents (e.g., aminoglycosides such as gentamicin or neomycin, other systemic polymyxins): if Polymix is applied over large areas of denuded or severely damaged skin, systemic absorption of polymyxin B can increase; concurrent use of other nephrotoxic/ototoxic drugs in this setting may theoretically increase the risk of kidney or nerve toxicity.
• Other topical antibiotics or irritant topical products: concurrent application of multiple topical antimicrobial products to the same site is not recommended, as it may increase local irritation, sensitization risk, and does not add clinical benefit.

Inform your physician or pharmacist of all other medicines, including other topical products, that you are using before starting Polymix.

Polymix is generally well tolerated when used as directed, since systemic absorption from topical use is minimal. Reported adverse effects include:

• Common (local): mild itching, burning, stinging, or redness at the application site.
• Less common: allergic contact dermatitis or skin rash from sensitization to bacitracin or polymyxin B, which may worsen with repeated or prolonged use.
• Rare but serious: severe allergic reactions, including anaphylaxis, have been reported rarely with topical bacitracin-containing products; discontinue immediately and seek emergency medical care if signs of a severe allergic reaction (swelling of the face/throat, difficulty breathing, hives) occur.
• Ophthalmic use: transient burning, stinging, itching, or blurred vision immediately after application.

If irritation, rash, or worsening of the condition occurs, stop using Polymix and consult a physician.

Pregnancy: There are no adequate, well-controlled studies of Polymix in pregnant women. Because systemic absorption from topical or ophthalmic use is minimal, risk to the fetus is expected to be low, but Polymix should be used during pregnancy only if clearly needed and the potential benefit justifies any potential risk; consult a physician before use.

Lactation: It is not known whether topically or ophthalmically applied bacitracin or polymyxin B is excreted in human milk in clinically significant amounts. Because systemic absorption is minimal, use is generally considered acceptable when needed, but breastfeeding mothers should avoid applying Polymix directly to the nipple/areola area and should consult a physician before use.

The following precautions apply to the use of Polymix:

• For external (topical skin) or ophthalmic use only, according to the specific formulation; do not swallow or inject.
• Do not use on the eyes unless the product is specifically labeled and prescribed as an ophthalmic formulation.
• Stop use and consult a physician if the treated area shows signs of worsening infection, spreading redness, swelling, pus, fever, or if the condition does not improve within a few days.
• Not adequate as sole treatment for deep puncture wounds, animal bites, or serious burns; these require prompt medical evaluation.
• Discontinue immediately if signs of allergic sensitization (increasing itching, rash, swelling) appear.
• Avoid prolonged or repeated use beyond what is recommended, as this increases the risk of allergic sensitization and antibiotic resistance; Polymix should not be used prophylactically on all wounds indiscriminately.
• Antibiotic stewardship: Take/use Polymix exactly as prescribed by your physician; do not stop, extend, skip doses/applications, or share this medicine with others without medical advice.

Topical overdose (excessive application) of Polymix is unlikely to cause serious systemic toxicity because absorption through intact skin is minimal; excess product can simply be wiped away, and persistent irritation should be discussed with a physician.

If Polymix is accidentally swallowed in significant amount, or if a severe allergic reaction or unexpected systemic symptoms (such as difficulty breathing, facial swelling, dizziness, or reduced urination suggesting kidney effects from large-scale absorption) occur, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed and out of the reach of children.

Pediatric patients: Polymix topical ointment is generally used in children over 2 years of age for minor wound care under adult supervision; use in younger children should be guided by a physician. Ophthalmic Polymix may be used in children when prescribed by a physician; safety and efficacy in neonates have not been well established.

Elderly patients: No specific dose adjustment is required for topical or ophthalmic use in elderly patients; general precautions regarding skin integrity and wound assessment apply.

Renal or hepatic impairment: Because systemic absorption from topical or ophthalmic Polymix is normally negligible, no dose adjustment is generally required. However, if Polymix is applied over large areas of severely damaged or denuded skin, systemic absorption of polymyxin B may increase, and caution is advised in patients with renal impairment due to the theoretical risk of nephrotoxicity.

Polymix is generally intended for short-term use. For minor skin wounds, treatment is typically limited to 5 to 7 days; if the condition does not improve or worsens within this period, a physician should be consulted. For ophthalmic infections, duration (commonly around 7 to 10 days) should be determined and monitored by the prescribing physician based on clinical response.

Bacitracin Zinc + Polymyxin B Sulfate is classified as a topical antibacterial combination consisting of a polypeptide antibiotic (bacitracin) and a polymyxin-class cyclic polypeptide antibiotic (polymyxin B).

Bacitracin Zinc + Polymyxin B Sulfate works through two complementary mechanisms: bacitracin zinc inhibits bacterial cell wall synthesis by blocking recycling of the lipid carrier molecule needed for peptidoglycan transport, mainly affecting gram-positive bacteria; polymyxin B sulfate disrupts the outer cell membrane of gram-negative bacteria by binding to lipopolysaccharide, increasing membrane permeability and causing cell death. Combined, Bacitracin Zinc + Polymyxin B Sulfate provides antibacterial activity spanning both gram-positive and gram-negative organisms commonly responsible for minor superficial infections.

Polymix topical ointment may be used in children, generally over 2 years of age, for the prevention or treatment of minor skin infections under adult supervision, following the same application guidance as for adults but with close monitoring. Ophthalmic Polymix may be used in pediatric patients when prescribed by a physician for superficial eye infections. Safety and efficacy of Polymix have not been well established in neonates and very young infants, and use in this group should only occur under direct physician guidance.